Incidence and risk factors of myelosuppression of linezolid in patients with drugresistant tuberculosis: A scoping review.

This document summarizes a scoping review on the use of linezolid in the treatment of drug-resistant tuberculosis (DR-TB). The review found that myelosuppression, particularly anemia, was a common side effect of linezolid treatment in DR-TB patients. Risk factors for myelosuppression included HIV co-infection, age, and high exposure to linezolid. Regular monitoring of hematologic parameters is recommended during linezolid treatment, especially in patients with these risk factors. The document also provides insights into dosing strategies, pharmacokinetics, and the importance of considering factors such as age and renal function when using linezolid in TB treatment. [Extracted from the article]